Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma.

Richard F RiedelVictoria ChuaAnia MoradkhaniNatalie KrkyanAmir AhariAtsushi OsadaSant P Chawla

Published in: The oncologist (2022)

NC-6300 was well tolerated, showing promising activity in angiosarcoma patients without prior anthracycline treatment. NC-6300 warrants further investigation (ClinicalTrials.gov Identifier: NCT03168061).

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
patient reported outcomes
combination therapy
smoking cessation